Can a woman of reproductive age get pregnant after undergoing the MyoSure (transecervical resection) procedure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Pregnancy Occur After MyoSure?

Yes, women can become pregnant after MyoSure (hysteroscopic tissue removal system) procedure, with evidence showing a pregnancy rate of 65.12% and improved time to conception compared to traditional hysteroscopic electroresection. 1

Fertility Outcomes After MyoSure

The most recent high-quality evidence demonstrates that MyoSure not only preserves fertility but may enhance reproductive outcomes:

  • Pregnancy rates of 65.12% were achieved in women of reproductive age after MyoSure treatment for benign intrauterine lesions, significantly higher than the 54.55% rate with traditional electroresection (P = 0.045). 1

  • Time to pregnancy was significantly shorter at 13.14 ± 7.85 months compared to 16.26 ± 8.22 months with electroresection (P = 0.040). 1

  • Term live birth rates, premature birth rates, and abortion rates showed no significant differences between MyoSure and traditional methods, indicating comparable pregnancy safety profiles. 1

Mechanism of Fertility Preservation

MyoSure offers specific advantages that support fertility:

  • Reduced intrauterine adhesion formation: The American Fertility Society adhesion scores improved significantly more with MyoSure (2.90 ± 1.29 points) compared to electroresection (1.31 ± 0.89 points, P = 0.025). 1 This is critical because intrauterine adhesions are a major cause of infertility after hysteroscopic procedures.

  • Shorter operative times minimize endometrial trauma for type 0 and type I myomas, endometrial polyps, and retained products of conception. 1

Important Clinical Considerations

Lesion Type Matters

  • Type 0 and Type I submucosal fibroids: MyoSure demonstrates clear advantages with faster operative times and excellent fertility outcomes. 1

  • Type II myomas (>50% intramural component): MyoSure has limitations with lower complete resection rates compared to electroresection. 1 For these lesions, traditional electroresection or laparoscopic myomectomy may be more appropriate. 2

Supporting Evidence from Broader Hysteroscopic Myomectomy Data

The fertility benefits of hysteroscopic removal of submucosal fibroids are well-established:

  • Pregnancy rates of 85% after hysteroscopic myomectomy with live birth rates of 65% have been reported in retrospective studies. 2

  • Submucosal fibroids have the most detrimental effect on fertility with pregnancy rates of only 10% and implantation rates of 4.3% when left untreated. 2

  • Hysteroscopic myomectomy is the treatment of choice for submucosal fibroids to improve conception and pregnancy rates. 2

Post-Procedure Recommendations

Timing of conception attempts: While the evidence doesn't specify a mandatory waiting period after MyoSure, the improved adhesion scores and shorter operative times suggest earlier attempts may be reasonable compared to traditional methods. 1

Follow-up evaluation: Second-look hysteroscopy can assess for intrauterine adhesions, though MyoSure demonstrates significantly better adhesion outcomes than electroresection. 1

Critical Pitfall to Avoid

Do not assume MyoSure is appropriate for all fibroid types. For type II myomas with significant intramural components (>50%), comprehensive pre-procedure evaluation is required, and alternative approaches such as laparoscopic myomectomy should be considered. 1 2 The complete resection rate is lower with MyoSure for these lesions, which could compromise fertility outcomes.

References

Research

Comparative analysis of the clinical efficacy and reproductive outcomes of the hysteroscopic tissue removal system (MyoSure) and hysteroscopic electroresection in the treatment of benign intrauterine lesions.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023

Guideline

Management of Uterine Fibroids in Infertile Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.